About SkyePharma PLC (LON:SKP)
Skyepharma Ltd, formerly Skyepharma PLC, is a drug delivery company engaged in the development of oral and inhalation products. The Company operates as an independent developer of complex pharmaceutical products for global markets. Its principal activities are the generation and development of product and drug delivery technology concepts, involving the application of its inhalation and oral technologies. It operates through the segment of development and supply of pharmaceutical products. It is also involved in the supply of products to its marketing partners, as in the case for flutiform and over seven oral products manufactured in its Lyon Facility. It operates primarily for respiratory applications. Its inhalation products include Relvar Ellipta/Breo Ellipta, Anoro Ellipta and Incruse Ellipta. Its oral products include RAYOS/LODOTRA, Requip Once-a-day, Xatral/Uroxatral, Madopar DR/Prolopa, Sular, ZYFLO CR, Paxil CR, Diclofenacratiopharm Uno, Triglide and Coruno.
Industry, Sector and Symbol:
- Industry: Pharmaceuticals - NEC
- Sub-Industry: N/A
- Sector: Pharmaceuticals - NEC
- Symbol: LON:SKP
- CUSIP: N/A
- Web: N/A
- Trailing EPS: GBX 0.25
- Net Margins: 32.70%
- Return on Equity: 79.41%
- Return on Assets: 35.64%
- Outstanding Shares: 105,910,000
Frequently Asked Questions for SkyePharma PLC (LON:SKP)
What is SkyePharma PLC's stock symbol?
SkyePharma PLC trades on the London Stock Exchange (LON) under the ticker symbol "SKP."
Who are some of SkyePharma PLC's key competitors?
Some companies that are related to SkyePharma PLC include AA PLC (AA), Telecom plus PLC (TEP), Morgan Advanced Materials PLC (MGAM), Dignity Plc (DTY), Ultra Electronics Holdings plc (ULE), Pets at Home Group Plc (PETS), Marshalls plc (MSLH), Rank Group PLC (RNK), Keywords Studios plc (KWS), Fidessa group plc (FDSA), OneSavings Bank PLC (OSB), CLS Holdings plc (CLI), Stagecoach Group plc (SGC), Jimmy Choo PLC (CHOO), 888 Holdings plc (888), McCarthy & Stone plc (MCS), First Derivatives plc (FDP) and Purplebricks Group PLC (PURP).
How do I buy SkyePharma PLC stock?
Shares of SkyePharma PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is SkyePharma PLC's stock price today?
One share of SkyePharma PLC stock can currently be purchased for approximately GBX 444.
How big of a company is SkyePharma PLC?
SkyePharma PLC has a market capitalization of £470.25 million.
How can I contact SkyePharma PLC?
SkyePharma PLC's mailing address is 46-48 Grosvenor Gardens, LONDON, SW1W 0EB, United Kingdom. The company can be reached via phone at +44-20-78810524.
MarketBeat Community Rating for SkyePharma PLC (LON SKP)MarketBeat's community ratings are surveys of what our community members think about SkyePharma PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for SkyePharma PLC (LON:SKP) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for SkyePharma PLC (LON:SKP)
Analysts' Ratings History for SkyePharma PLC (LON:SKP)
(Data available from 11/21/2015 forward)
|2/17/2016||Stifel Nicolaus||Reiterated Rating||Buy||GBX 460|
|1/28/2016||N+1 Singer||Reiterated Rating||Corporate|
|12/23/2015||RX Securities||Reiterated Rating||Buy|
Earnings History for SkyePharma PLC (LON:SKP)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for SkyePharma PLC (LON:SKP)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for SkyePharma PLC (LON:SKP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for SkyePharma PLC (LON SKP)
Insider Trades by Quarter for SkyePharma PLC (LON SKP)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
Latest Headlines for SkyePharma PLC (LON SKP)
Financials are not available for this stock.
SkyePharma PLC (LON SKP) Chart for Tuesday, November, 21, 2017